ABVC BIOPHARMA INC
ABVCNASDAQTrading Snapshot
- Day Range
- $1.03 – $1.05
- 52-Week Range
- $0.71 – $3.40
- Volume
- $2.84B
- Avg Volume
- $3.17B
- Shares Outstanding
- 26.0M
- Next Earnings
- Oct 20, 2026
Fundamentals Snapshot
- Annual Revenue
- $6M
- Last Q Revenue
- $1M
- P/E Ratio
- -3.5
- P/S Ratio
- -34.0x
- EPS (TTM)
- $-0.30
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +74.6%
Why Investors Own ABVC
- ✓High-growth profile — revenue up +49.5% YoY with expanding US Equity exposure.
- ✓Healthy economics — 29% gross margin and 7% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
ABVC BIOPHARMA INC
ABVC
StockOtter · stockotter.spaceAbout ABVC BIOPHARMA INC
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States. The company's pipeline includes several key candidates: ABV-1501, currently undergoing Phase I/II clinical trials, is being developed as a combination treatment for triple-negative breast cancer. ABV-1504 has successfully completed Phase II clinical trials for major depressive disorders. ABV-1505 is progressing through Phase II clinical studies for attention deficit hyperactivity disorder (ADHD). ABV-1703 has concluded its Phase I clinical trials for the treatment of pancreatic cancer. ABV-1702 has also finished Phase I clinical investigations for myelodysplastic syndromes. ABV-1601 is in Phase I/II clinical trials, aimed at alleviating depression in individuals with cancer. ABV-1701 Vitargus is in development to treat conditions such as retinal detachment or vitreous hemorrhage. ABVC BioPharma maintains strategic alliances, including a co-development arrangement with Rgene Corporation, alongside collaborative agreements with BioHopeKing Corporation and BioFirst Corporation. The company's headquarters are located in Fremont, California, and it operates as a subsidiary of YuanGene Corporation.
